SCHEMBL1787760

SCHEMBL1787760

O=C(NCc1ccc(Cl)cc1)c1ccc2c(c1)CCN(C1=CC=C1)CC2

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.48
KMT2A Q03164 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
IDO1 P14902 1/20 0.46
TP53 P04637 1/20 0.45
THRB P10828 1/20 0.45
MEN1 O00255 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44
LMNA P02545 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
OPRK1 P41145 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1789578 0.90 NR1H4 (0.48) MAPTKMT2A
SCHEMBL1789725 0.89 EPHX2 (0.48) MAPTSMN1; SMN2KMT2ATP53MEN1
SCHEMBL1788808 0.89 RAB9A (0.48) MAPTSMN1; SMN2TP53RAB9ALMNA
SCHEMBL1790168 0.89 IDO1 (0.48) SMN1; SMN2KMT2AIDO1MEN1LMNA
SCHEMBL1786904 0.87 MAPT (0.44) MAPTSMN1; SMN2KMT2ATP53THRB
SCHEMBL1791894 0.87 ALDH1A1 (0.48) MAPTSMN1; SMN2KMT2ATDP1MEN1
SCHEMBL1787455 0.86 MAPT (0.55) MAPTSMN1; SMN2KMT2ATP53THRB
SCHEMBL1790575 0.86 LSS (0.50)
SCHEMBL1792318 0.85 TP53 (0.44) IDO1TP53THRBLMNA
SCHEMBL1789773 0.83 NAMPT (0.48) MAPTKMT2ATP53LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326625-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2011-06-01 EP disclosed
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-26 US disclosed
WO-2010007382-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124626-A1 BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS HRH4, HRH3, HRH2 MAPT 3598/4885SMN1; SMN2 4393/4885KMT2A 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.